Two surrogate markers commonly used in multiple sclerosis (MS) clinical trials are near-perfect measures of the effect of treatment with interferon, researchers reported.
In a statistical analysis of patients in a major clinical trial, the two markers -- T2 lesions seen on MRI and relapses -- accounted for all of the effect of interferon ß-1a on disease progression, according to Maria Pia Sormani, PhD, of the University of Genoa in Italy, and colleagues.
The findings provide "strong scientific support" for the use of the two markers in clinical trials of interferon and drugs with a similar mechanism, Sormani and colleagues reported in the November 1 issue of Neurology.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1765